Skip to main content
BOSTON SCIENTIFIC CORP logo

BOSTON SCIENTIFIC CORP — Investor Relations & Filings

Ticker · BSX ISIN · US1011371077 LEI · Y6ZDD9FP4P8JSSJMW954 US Manufacturing
Open in API
Filings indexed 3,157 across all filing types
Latest filing 2024-01-31 Board/Management Inform…
Country US United States of America
Listing US BSX

About BOSTON SCIENTIFIC CORP

https://www.bostonscientific.com/en-US/…

Boston Scientific Corporation is a global medical technology company that develops, manufactures, and commercializes a broad range of high-performance medical devices. The company's products are used in various minimally invasive, interventional medical specialties, including cardiology, endoscopy, neuromodulation, urology, and pelvic health. Focused on transforming lives through innovative solutions, Boston Scientific is dedicated to improving the health of patients worldwide by addressing complex healthcare challenges and enhancing clinical outcomes.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 26, 2024, by Boston Scientific Corporation. The key content is under Item 5.02, which details the departure and appointment of senior officers: Jonathan Monson appointed as Senior Vice President, Investor Relations, and Emily Woodworth appointed as Senior Vice President, Global Controller and Chief Accounting Officer. This is a clear announcement of changes in the company's senior management. The document does not contain financial statements or detailed financial data, nor is it an earnings release or annual report. It is not a proxy statement or voting result. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4637 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2024-01-31 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 31, 2024, reporting the issuance of a press release announcing financial results for the fourth quarter and full year ended December 31, 2023. The document explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document length is 3734 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing the earnings data itself. According to the rules, such a document is classified as an Earnings Release (ER) since it announces quarterly/periodical financial results with key highlights only, and is not a full financial report or detailed management discussion. Therefore, the appropriate classification is ER with high confidence.
2024-01-31 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-01-25 English
Director's Dealing 2024
Director's Dealing
2024-01-16 English
Regulatory Filings 2024
Regulatory Filings
2024-01-12 English
Director's Dealing 2024
Director's Dealing
2024-01-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.